AlphaBiomics develops microbiome-based predictive diagnostics and companion therapeutics to enhance the safety and efficacy of drug therapies. By leveraging microbiome data, the company addresses the challenge of variable patient responses to medications, enabling more personalized treatment options.
Funding
$110K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Variable patient responses to medications pose a significant challenge in drug therapy. This variability can lead to reduced efficacy and increased adverse effects, hindering optimal treatment outcomes.
Solution
AlphaBiomics develops microbiome-based predictive diagnostics and companion therapeutics to address the challenge of variable patient responses to medications. By analyzing an individual's microbiome, AlphaBiomics aims to predict their response to specific drugs, enabling more personalized and effective treatment strategies. Their approach involves identifying microbial biomarkers that correlate with drug efficacy and toxicity, allowing clinicians to tailor prescriptions based on a patient's unique microbiome profile. This personalized approach has the potential to improve treatment outcomes, reduce adverse effects, and enhance the overall safety and efficacy of drug therapies.
Target Audience
The primary target audience includes pharmaceutical companies, healthcare providers, and research institutions seeking to improve drug efficacy and personalize treatment strategies.
Features
- Microbiome-based predictive diagnostics for personalized drug selection
- Companion therapeutics to modulate the microbiome and enhance drug efficacy
- Identification of microbial biomarkers associated with drug response